Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients.
Elderly patient
Immune checkpoint inhibitors
NSCLC
PD-1/PD-L1
biological big data
precision oncology
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
07 May 2019
07 May 2019
Historique:
received:
26
03
2019
revised:
02
05
2019
accepted:
03
05
2019
entrez:
10
5
2019
pubmed:
10
5
2019
medline:
4
9
2019
Statut:
epublish
Résumé
The therapeutic scenario for elderly patients with advanced NSCLC has been limited to radiotherapy and chemotherapy. Recently, a novel therapeutic approach based on targeting the immune-checkpoints has showed noteworthy results in advanced NSCLC. PD1/PD-L1 pathway is co-opted by tumor cells through the expression of PD-L1 on the tumor cell surface and on cells within the microenvironment, leading to suppression of anti-tumor cytolytic T-cell activity by the tumor. The success of immune-checkpoints inhibitors in clinical trials led to rapid approval by the FDA and EMA. Currently, data regarding efficacy and safety of ICIs in older subjects is limited by the poor number of elderly recruited in clinical trials. Careful assessment and management of comorbidities is essential to achieve better outcomes and limit the immune related adverse events in elderly NSCLC patients.
Identifiants
pubmed: 31067796
pii: ijms20092258
doi: 10.3390/ijms20092258
pmc: PMC6539213
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Pulm Pharmacol Ther. 2019 Apr;55:25-30
pubmed: 30654148
J Thorac Oncol. 2011 May;6(5):934-41
pubmed: 21372743
Cancer Res. 2011 Aug 15;71(16):5393-9
pubmed: 21724589
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Immunol Lett. 2011 Jan 30;134(2):157-60
pubmed: 20951741
Science. 2018 Jan 5;359(6371):104-108
pubmed: 29302014
Nature. 2012 Aug 9;488(7410):178-84
pubmed: 22797518
J Immunol. 2004 Feb 1;172(3):1483-90
pubmed: 14734725
Nat Rev Immunol. 2013 May;13(5):376-89
pubmed: 23584423
PLoS One. 2017 Aug 7;12(8):e0182356
pubmed: 28786985
Int J Mol Sci. 2019 Feb 15;20(4):
pubmed: 30781341
Immun Ageing. 2012 Jul 25;9(1):15
pubmed: 22830639
J Leukoc Biol. 2013 Apr;93(4):633-7
pubmed: 23341539
Nature. 2006 Feb 9;439(7077):682-7
pubmed: 16382236
Cancer Treat Rev. 2016 Apr;45:30-7
pubmed: 26946217
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
PLoS One. 2010 May 17;5(5):e10667
pubmed: 20498852
N Engl J Med. 1999 Dec 30;341(27):2061-7
pubmed: 10615079
Int J Surg. 2016 Sep;33 Suppl 1:S4-8
pubmed: 27255127
Int J Cancer. 2012 Jul 1;131(1):83-94
pubmed: 21815143
Cell. 2013 Jun 6;153(6):1194-217
pubmed: 23746838
J Thorac Oncol. 2019 Mar;14(3):547-552
pubmed: 30476576
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Exp Gerontol. 2015 Jan;61:84-91
pubmed: 25479230
J Cardiothorac Surg. 2019 Mar 4;14(1):50
pubmed: 30832704
Int J Surg. 2016 Sep;33 Suppl 1:S30-5
pubmed: 27255131
Eur J Immunol. 2015 May;45(5):1441-51
pubmed: 25707450
J Geriatr Oncol. 2017 May;8(3):229-235
pubmed: 28223073
Anticancer Res. 2015 May;35(5):2769-74
pubmed: 25964556
Ann Ital Chir. 2016 Jan 29;87(ePub):
pubmed: 26829462
BMC Geriatr. 2014 Apr 17;14:50
pubmed: 24742120
J Invest Dermatol. 2015 Jul;135(7):1752-1762
pubmed: 25734814
Ann Ital Chir. 2015 Sep 24;86(ePub):
pubmed: 26394843
Nature. 2007 Jun 7;447(7145):725-9
pubmed: 17554309
J Clin Oncol. 2005 May 1;23(13):3125-37
pubmed: 15860872
Aging Cell. 2010 Oct;9(5):785-98
pubmed: 20653631
J Nutr Biochem. 2018 Mar;53:72-80
pubmed: 29195133
J Immunol. 2015 May 1;194(9):4073-80
pubmed: 25888703
Trends Immunol. 2009 Jul;30(7):306-12
pubmed: 19540809
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Curr Pharm Biotechnol. 2018;19(9):700-707
pubmed: 30332949
Immun Ageing. 2008 Jul 25;5:6
pubmed: 18657274
Ageing Res Rev. 2015 Sep;23(Pt A):116-23
pubmed: 25676139
Hum Immunol. 2004 Feb;65(2):142-56
pubmed: 14969769
J Immunol. 2005 Jun 1;174(11):7446-52
pubmed: 15905594
Crit Rev Oncog. 2013;18(6):573-83
pubmed: 24579736
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Environ Pollut. 2012 Dec;171:162-7
pubmed: 22922455
BMC Immunol. 2013 Oct 01;14:45
pubmed: 24083425
Ann Oncol. 2016 Apr;27(4):559-74
pubmed: 26715621
Immunol Rev. 2005 Jun;205:220-8
pubmed: 15882356
Open Med (Wars). 2016 Nov 19;11(1):443-448
pubmed: 28352834
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Expert Opin Biol Ther. 2017 May;17(5):565-571
pubmed: 28276698
Ann N Y Acad Sci. 2006 May;1067:152-7
pubmed: 16803980
Medicines (Basel). 2018 Sep 10;5(3):
pubmed: 30201858
Clin Immunol. 2008 Apr;127(1):107-18
pubmed: 18222733
Respir Res. 2015 Jun 24;16:74
pubmed: 26104294
Immunol Rev. 2005 Jun;205:7-17
pubmed: 15882341
Exp Gerontol. 2008 Apr;43(4):266-74
pubmed: 18215485
In Vivo. 2014 Jul-Aug;28(4):557-61
pubmed: 24982222
Cancer Treat Rev. 2017 Nov;60:60-68
pubmed: 28889085
Oncoimmunology. 2019 Feb 3;8(4):e1568810
pubmed: 30906662
J Clin Oncol. 2007 Dec 10;25(35):5570-7
pubmed: 18065729
Blood. 2010 Sep 30;116(13):2286-94
pubmed: 20460501
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Transl Cancer Res. 2019 Mar;8(Suppl 2):S103-S105
pubmed: 35117074
Am J Respir Crit Care Med. 2013 Oct 1;188(7):770-5
pubmed: 23841470
Pulm Pharmacol Ther. 2017 Aug;45:114-120
pubmed: 28506662
Curr Biol. 2016 Sep 26;26(18):R832-R833
pubmed: 27676296
Open Med (Wars). 2016 Jun 23;11(1):220-225
pubmed: 28352798
Blood. 2003 Apr 1;101(7):2711-20
pubmed: 12433688
Environ Pollut. 2012 Feb;161:64-9
pubmed: 22230069
J Immunother Cancer. 2018 Apr 4;6(1):26
pubmed: 29618381
Clin Ther. 2018 Apr;40(4):526-534
pubmed: 29573852
Lancet Oncol. 2015 Mar;16(3):257-65
pubmed: 25704439
EMBO Rep. 2007 Mar;8(3):220-3
pubmed: 17304236
Curr Opin Pharmacol. 2018 Jun;40:46-50
pubmed: 29525401
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4586-91
pubmed: 20571116